Amgen (BUE:AMGN) Debt-to-Revenue

: 1.97 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ARS520,923 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ARS22,804,370 Mil. Amgen's annualized Revenue for the quarter that ended in Dec. 2023 was ARS11,835,024 Mil. Amgen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 1.97.

Amgen Debt-to-Revenue Historical Data

The historical data trend for Amgen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

1.28

1.30

1.28

1.48

2.29

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue																1.42	2.52	2.20	2.19	1.97

Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen Debt-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amgen's Debt-to-Revenue falls into.

Amgen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Amgen's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(520923	+	22804370.021)	/	10176590.009
	=	2.29

Amgen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(520923	+	22804370.021)	/	11835024.012
	=	1.97

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Amgen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amgen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.